Berger noted that while Iclusig is currently used as a last resort for patients where other treatments have failed, the company has studies underway looking at its use as a first-line treatment, which would open up its possibilities greatly. He said the main challenge for Ariad now is educating doctors on its safety and performance.
When asked about whether Ariad is a takeover target now that it has approval for Iclusig, Berger said biotech companies can be built to be bought or they can be built for the long term. Ariad is one of the few being built as one that discovers, develops and markets its findings on a global scale.
Cramer said Ariad is doing all the right things and he continues to be a believer in the company.
On the LINE
In his second "Executive Decision" segment, Cramer sat down with Mark Ellis, chairman, president and CEO of
(LINE - Get Report), an oil and gas master limited partnership with a 7.7% yield.
Ellis explained there is a lot of misunderstanding about the company's hedging strategy, which doesn't follow standard accounting metrics. He said Linn likes to take commodity risk out of the equation when it does a deal, which is why it'll often hedge oil prices for five years. To date, there have been no challenges to the company's accounting principles, he said, and Linn continues to pay regular dividends.
When asked about Linn's recent acquisition of assets from
and the acquisition of
, Ellis said that BP's assets are terrific but they were not core assets for BP, which is why they make more sense as a part of Linn. As for Berry, Ellis said there is a lot of hidden potential locked up in Berry's oil fields.
Turning to our nation's energy policy, Ellis said the U.S. still has a lot of undiscovered oil and gas reserves and he feels the U.S. has the technology to become energy independent if it would adopt an energy policy that made sense.
Cramer continued his support for Linn, reminding investors that for 401(k) and IRA accounts they should consider
, which is a subsidiary that owns shares of Linn and avoids arcane tax rules surrounding MLPs and tax-deferred accounts.
In the Lightning Round, Cramer was bullish on
Nordic American Tanker
Whole Foods Markets
Cramer was bearish on
Ship Finance International
Harris Teeter Supermarkets
In a third "Executive Decision" segment, Cramer spoke with Richard Pops, chairman and CEO of
, another biotech company that's been featured many times on "Mad Money." Shares of Alkermes are up 20% since Cramer last sat down with Pops in May 2012.
Pops said Alkermes will be seeing new competition for some of its anti-psychotic drugs, but that's actually a good thing as it shows there's plenty of growth in that area. He characterized it as the beginning for a whole new class of drugs and not the end for Alkermes' family of drugs.
Pops also had positive things to say about Vivitrol, his company's monthly injectable treatment for alcohol and opiate dependence. He said the drug has been a big success and patients taking the treatment simply will not relapse while on the medication. This is great news for those in the criminal justice system, he said, as many need to stay off of drugs as a condition of their parole.
Cramer said Alkermes is yet another example of a biotech company doing great and important work.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer opined on the state of the retail sector, which was supposed to be crushed by macro-economic headwinds.
Cramer said he's never been a fan of "top down" analysis as it's rarely right and often produces spectacular losses. While in theory it made sense that the American consumer would be hurt by rising gas prices and increased payroll taxes, retailer after retailer, from
, proved that theory wrong.
That's why Cramer said it's time to circle back and buy some
and Whole Foods, two stocks that have been out of favor as of late, but are likely to continue their march higher very soon.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,